Table 2.
Demographics and patient characteristics
| Characteristic | Overall (n=28) | Regimen A (n=19) | Regimen B (n=9) |
| Diagnosis, n (%) | |||
| MSS-CRC | 15 (54) | 10 (53) | 5 (56) |
| PR-OC | 4 (14) | 2 (11) | 2 (22) |
| ER+HER2- BC | 9 (32) | 7 (37) | 2 (22) |
| Median age (range) y | 56 (36–78) | 58 (36–78) | 52 (36–64) |
| Gender | |||
| Male | 9 (32) | 8 (42) | 1 (11) |
| Female | 19 (68) | 11 (58) | 8 (89) |
| ECOG PS | |||
| 0 | 7 (25) | 6 (32) | 1 (11) |
| 1 | 21 (75) | 13 (68) | 8 (89) |
| Prior systemic therapies (range) | 7 (3–12) | 7 (3–12) | 5 (3–8) |
| Prior treatment | |||
| Surgery | 28 (100) | 19 (100) | 9 (100) |
| Radiation | 18 (64) | 12 (63) | 6 (67) |
| PD-L1 tumor Staining at baseline | |||
| (SP263) ≥ 25%* | 0 | 0 | 0 |
*PD-L1 expression in tumor cells was assessed by immunohistochemistry using VENTANA SP263 assay (Roche Diagnostics), with positivity defined as staining in tumor cells >25%.
ECOG PS, Eastern Cooperative Oncology Group performance status; ER+HER2- BC, estrogen receptor positive, HER2 negative breast cancer; MSS-CRC, microsatellite stable colorectal cancer; PD-L1, programmed cell death-ligand 1; PR-OC, platinum resistant ovarian cancer.